The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...
Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for cancer patients. Enoby targets bone loss in patients on hormone-based ...
Bosaya and Aukelso are FDA-approved biosimilars for managing bone health in cancer patients, offering cost-effective alternatives to Prolia and Xgeva. Bosaya targets bone loss prevention in prostate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback